The second multi-stakeholder event on biosimilar medicinal products was held on 20 June 2016 in Brussels.
IMS Health presented the update report on the 'Impact of Biosimilar Competition', including 5 observations.
In the framework of this workshop, the European Commission decided to launch an update of the Q&A for patients with a particular focus on the direct involvement of patient representatives.
The Q&A document was first published in 2013 as part of the consensus information paper, 'What you need to know about biosimilar medicinal products'. The main objective of the revision was to address patients' priorities in terms of the need for information in language that is easy to understand, despite the complexity of the concept.